Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade) for the treatment of relapsed/refractory multiple myeloma (MM) and mantle cell lymphoma, it has become clear that new inhibitors are needed that have a better therapeutic ratio, can overcome inherent and acquired bortezomib resistance and exhibit broader anti-cancer activities. Marizomib (NPI-0052; salinosporamide A) is a structurally and pharmacologically unique β-lactone-γ-lactam proteasome inhibitor that may fulfill these unmet needs. The potent and sustained inhibition of all three proteolytic activities of the proteasome by marizomib has inspired extensive preclinical evaluation in a variety of hematologic and solid tumor models, where it is efficacious as a single agent and in combination with biologics, chemotherapeutics and targeted therapeutic agents. Specifically, marizomib has been evaluated in models for multiple myeloma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, chronic and acute lymphocytic leukemia, as well as glioma, colorectal and pancreatic cancer models, and has exhibited synergistic activities in tumor models in combination with bortezomib, the immunomodulatory agent lenalidomide (Revlimid), and various histone deacetylase inhibitors. These and other studies provided the framework for ongoing clinical trials in patients with MM, lymphomas, leukemias and solid tumors, including those who have failed bortezomib treatment, as well as in patients with diagnoses where other proteasome inhibitors have not demonstrated significant efficacy. This review captures the remarkable translational studies and contributions from many collaborators that have advanced marizomib from seabed to bench to bedside.
Nereus Pharmaceuticals, Inc., 10480 Wateridge Circle, San Diego, CA 92121, USA. mpalladino@nereuspharm.com
B C
BC
Potts
M X
MX
Albitar
K C
KC
Anderson
S
S
Baritaki
C
C
Berkers
B
B
Bonavida
J
J
Chandra
D
D
Chauhan
J C
JC
Cusack
W
W
Fenical
I M
IM
Ghobrial
M
M
Groll
P R
PR
Jensen
K S
KS
Lam
G K
GK
Lloyd
W
W
McBride
D J
DJ
McConkey
C P
CP
Miller
S T C
ST
Neuteboom
Y
Y
Oki
H
H
Ovaa
F
F
Pajonk
P G
PG
Richardson
A M
AM
Roccaro
C M
CM
Sloss
M A
MA
Spear
E
E
Valashi
A
A
Younes
M A
MA
Palladino
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011758:Pyrroles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007783:Lactones; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011758:Pyrroles; C475865:marizomib; D046988:Proteasome Endopeptidase Complex
J Clin Oncol. 2005 Feb 1;23(4):667-75
15613697
Appl Environ Microbiol. 2002 Oct;68(10):5005-11
12324350
Nat Rev Cancer. 2003 Oct;3(10):721-32
13130303
J Cell Biochem. 2009 Jul 1;107(4):600-8
19459166
J Med Chem. 2009 Oct 8;52(19):6163-7
19746976
Cancer Res. 2000 May 1;60(9):2323-30
10811101
Mol Cancer Ther. 2007 Apr;6(4):1387-99
17431117
J Antibiot (Tokyo). 2007 Jul;60(7):469-72
17721007
Structure. 2006 Mar;14(3):451-6
16531229
Mol Cancer Ther. 2002 Dec;1(14):1243-53
12516957
Oncogene. 2008 Apr 3;27(15):2243-8
17952120
Oncogene. 2010 Jan 21;29(3):451-62
19881538
Expert Opin Investig Drugs. 2009 Jul;18(7):957-71
19505187
N Engl J Med. 2005 Feb 24;352(8):804-15
15728813
J Nat Prod. 2009 Feb 27;72(2):295-7
19133779
Blood. 2004 Apr 1;103(7):2799-801
14576069
Mol Pharmacol. 2007 Jan;71(1):209-19
17028156
Clin Cancer Res. 2004 May 15;10(10):3371-6
15161691
Invest New Drugs. 2009 Feb;27(1):53-62
18618082
Mol Cell Biol. 2001 Nov;21(21):7207-17
11585904
Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53
15197486
Pharmacol Ther. 1979;7(1):91-121
392552
Br J Haematol. 2010 May;149(4):550-9
20331453
Biochem Pharmacol. 2005 Aug 1;70(3):394-406
15950952
Mol Cell Biol. 2007 Jun;27(12):4374-87
17438126
J Med Chem. 2009 May 14;52(9):3028-38
19348473
Oncol Rep. 2008 Nov;20(5):1283-7
18949434
Cancer Biol Ther. 2003 Nov-Dec;2(6):694-9
14688479
J Clin Oncol. 2008 May 10;26(14):2320-6
18467723
J Biol Chem. 1996 Mar 29;271(13):7273-6
8631740
Curr Top Med Chem. 2011 Dec;11(23):2850-78
21824111
Clin Pediatr (Phila). 2009 Jul;48(6):601-8
19264722
Oncologist. 2003;8(6):508-13
14657528
Clin Cancer Res. 2006 May 1;12(9):2902-11
16675587
Mol Cancer Ther. 2004 Jan;3(1):59-70
14749476
Cancer. 2008 Mar 15;112(6):1306-12
18224667
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1245-53
16904634
Annu Rev Pharmacol Toxicol. 2005;45:465-76
15822185
Cancer Cell. 2005 Nov;8(5):407-19
16286248
Blood. 2009 Oct 15;114(16):3439-47
19671918
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
Science. 2009 Jun 12;324(5933):1457-61
19460966
Cell Signal. 2010 Jul;22(7):984-1002
20096351
Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62
17379101
Cancer Res. 2007 Jul 1;67(13):6383-91
17616698
Clin Cancer Res. 2003 Oct 1;9(12):4570-7
14555532
J Biol Chem. 2006 Mar 31;281(13):8582-90
16455650
Drug Discov Today. 2010 Mar;15(5-6):243-9
20116451
Mol Cancer Ther. 2006 Jul;5(7):1836-43
16891470
Science. 1995 Apr 28;268(5210):533-9
7725097
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Cancer Sci. 2004 Oct;95(10):777-83
15504243
J Am Chem Soc. 2006 Apr 19;128(15):5136-41
16608349
J Surg Res. 2001 Sep;100(1):11-7
11516199
Blood. 2008 Apr 1;111(7):3906-7
18362222
Blood. 2007 Mar 1;109(5):2100-5
17095627
Blood. 2007 Jul 1;110(1):267-77
17356134
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):521-6
20133082
Cancer. 2004 Apr 15;100(8):1578-89
15073843
J Surg Res. 2004 Aug;120(2):178-88
15234211
N Engl J Med. 2008 Aug 28;359(9):906-17
18753647
Leuk Lymphoma. 2010 Jun;51(6):983-94
20367564
J Clin Oncol. 2006 Oct 20;24(30):4867-74
17001068
J Neurooncol. 2010 Oct;100(1):95-103
20213332
Cancer Res. 2009 Jul 15;69(14):5820-8
19584296
Clin Cancer Res. 2008 Dec 15;14(24):8132-42
19088028
Eur J Haematol. 2009 Jun;82(6):450-3
19187275
Clin Cancer Res. 2008 Mar 15;14(6):1649-57
18347166
Blood. 1993 Sep 15;82(6):1820-8
8104532
Blood. 2009 Apr 30;113(18):4289-99
19182209
Trends Microbiol. 2007 Nov;15(11):491-9
17997312
Cancer Res. 2002 Sep 1;62(17):4996-5000
12208752
J Nat Prod. 2007 Feb;70(2):269-76
17243724
Mar Drugs. 2010 Mar 25;8(4):835-80
20479958
Clin Cancer Res. 2007 Jun 1;13(11):3320-5
17545538
Hematology Am Soc Hematol Educ Program. 2003;:153-75
14633781
Blood. 2009 Jun 4;113(23):5927-37
19190249
Clin Cancer Res. 2008 Jan 15;14(2):549-58
18223231
Br J Clin Pharmacol. 2002 Sep;54(3):269-76
12236847
Expert Rev Mol Diagn. 2007 Sep;7(5):615-23
17892367
Oncogene. 2003 Nov 24;22(53):8628-33
14634624
Nat Rev Mol Cell Biol. 2005 Jun;6(6):439-48
15928708
Nat Biotechnol. 2003 Aug;21(8):897-902
12872133
J Org Chem. 2005 Aug 5;70(16):6196-203
16050677
Bioorg Med Chem. 2009 Mar 15;17(6):2175-80
19022674
Cancer Control. 2008 Oct;15(4):308-13
18813198
Nat Biotechnol. 2000 May;18(5):538-43
10802622
Cancer Res. 2009 Nov 1;69(21):8376-85
19843864
Science. 2009 Aug 14;325(5942):834-40
19608861
Mol Cell Biol. 2006 Aug;26(15):5895-907
16847340
Eur J Haematol. 2005 May;74(5):407-17
15813915
Blood. 2003 Apr 1;101(7):2507-13
12446458
Clin Lymphoma Myeloma. 2005 Nov;6(3):191-9
16354324
Semin Oncol. 2009 Dec;36 Suppl 3:S26-36
19963097
Mol Pharm. 2007 Sep-Oct;4(5):739-48
17708652
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9
12391322
Mol Cancer Ther. 2009 Jul;8(7):1995-2006
19567817
Clin Cancer Res. 2005 Aug 1;11(15):5526-33
16061869
Nat Med. 2003 Jul;9(7):969-73
12819780
Clin Chem. 2000 May;46(5):673-83
10794750
BioDrugs. 2006;20(1):13-23
16573348
Blood. 1996 Feb 1;87(3):1104-12
8562936
J Clin Oncol. 2005 Feb 1;23(4):676-84
15613699
Adv Enzyme Regul. 1984;22:27-55
6382953
Int J Cancer. 2007 Jul 15;121(2):431-41
17373661
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10376-81
17563368
Cancer Cell. 2004 May;5(5):417-21
15144949
Cancer. 2006 Nov 15;107(10):2482-9
17036355
Neoplasia. 2006 Dec;8(12):1037-41
17217621
J Clin Oncol. 2002 Nov 15;20(22):4420-7
12431963
J Natl Cancer Inst. 2009 Mar 4;101(5):350-9
19244169
J Clin Oncol. 2006 Jul 1;24(19):3113-20
16754936
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4
17875757
Cancer. 2006 Dec 1;107(11):2688-97
17075878
Clin Cancer Res. 2009 Jun 1;15(11):3820-6
19458051
J Immunol. 2007 Oct 15;179(8):5441-53
17911631
Blood. 2008 Mar 1;111(5):2765-75
18057228
Mol Cancer Ther. 2007 Mar;6(3):1062-9
17363499
Mol Cancer Ther. 2006 Sep;5(9):2251-60
16985059
Appl Microbiol Biotechnol. 2008 Apr;78(5):827-32
18239915
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):433-9
19084346
Int J Syst Evol Microbiol. 2005 Sep;55(Pt 5):1759-1766
16166663
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12295-300
19590008
Eur J Cancer. 2009 Jan;45(1):48-55
18809314
Cancer Res. 2007 Feb 15;67(4):1735-43
17308115
J Exp Ther Oncol. 2008;7(2):99-111
18771084
J Immunol. 2008 May 1;180(9):6199-210
18424742
Blood. 2007 Oct 1;110(7):2286-95
17609425
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93
11316563
Cancer Treat Rev. 2003 May;29 Suppl 1:3-9
12738238
Oncogene. 2007 Nov 22;26(53):7445-56
17563753
J Neurosurg. 1996 Dec;85(6):1056-65
8929495
Haematologica. 2008 Dec;93(12):1908-11
18768528
Nat Methods. 2005 May;2(5):357-62
15846363
Clin Cancer Res. 2006 Nov 15;12(22):6758-64
17121896
Cancer Res. 2010 Mar 1;70(5):1970-80
20160034
Chem Rev. 2007 Mar;107(3):687-717
17316053
Nat Chem Biol. 2008 Jan;4(1):69-74
18059261
Blood. 2008 Feb 1;111(3):1654-64
18006697
Br J Haematol. 2009 Aug;146(3):270-81
19500098
Cancer. 2006 Sep 1;107(5):916-24
16832816
Oncogene. 2005 Jan 13;24(3):344-54
15531918
Blood. 2008 May 1;111(9):4752-63
18316628
J Am Chem Soc. 2005 Jun 29;127(25):8974-6
15969573
Transl Oncol. 2010 Feb;3(1):50-5
20165695
BMC Cancer. 2005 Jul 07;5:76
16001975
J Cell Biochem. 2001 Apr 2-27;82(1):110-22
11400168
Cancer. 2009 May 15;115(10 Suppl):2262-72
19402056
Mol Cancer Ther. 2009 Feb;8(2):342-9
19174560
Br J Haematol. 2010 May;149(4):537-49
20331454
Clin Cancer Res. 2007 Dec 15;13(24):7271-9
18094407
Cancer Res. 2008 May 1;68(9):3379-88
18451165
Nature. 2006 May 25;441(7092):431-6
16724054
J Med Chem. 2005 Jun 2;48(11):3684-7
15916417
J Biol Chem. 2002 May 10;277(19):16639-47
11872748
Cell. 1994 Sep 9;78(5):773-85
8087845
Cancer Res. 2006 Apr 1;66(7):3773-81
16585204
Breast Cancer Res Treat. 2006 Nov;100(1):33-47
16807678
Eur J Haematol. 2001 Jan;66(1):1-6
11168500
Mol Cancer Ther. 2006 Dec;5(12):3032-41
17172406
Angew Chem Int Ed Engl. 2003 Jan 20;42(3):355-7
12548698
Nat Chem Biol. 2006 Dec;2(12):666-73
17108984
Leukemia. 2000 Aug;14(8):1509-13
10942251
Anticancer Res. 2004 Mar-Apr;24(2B):675-81
15161011
Cancer. 1995 Dec 15;76(12):2393-417
8625065
Ann Oncol. 2005 Oct;16(10):1654-61
16085692
Science. 1995 May 5;268(5211):726-31
7732382
Nature. 1997 Apr 3;386(6624):463-71
9087403
Curr Opin Chem Biol. 2002 Aug;6(4):493-500
12133726
Br J Cancer. 2009 May 5;100(9):1379-84
19401697
Mol Pharmacol. 2004 Dec;66(6):1478-90
15448190
J Med Chem. 2008 Nov 13;51(21):6711-24
18939815
Blood. 2005 Dec 1;106(12):3777-84
16099887
Oncogene. 2010 May 27;29(21):3146-52
20208558
J Org Chem. 2010 Jun 4;75(11):3882-5
20465296
Blood. 2002 Aug 1;100(3):768-73
12130484
J Gastrointest Surg. 2004 Dec;8(8):1072-8
15585396
Cancer Res. 2003 Oct 1;63(19):6174-7
14559800
Cancer Res. 2009 Mar 1;69(5):1836-43
19244104
Biochem J. 1999 Dec 1;344 Pt 2:477-85
10567231
Clin Cancer Res. 2001 May;7(5):1419-28
11350913
J Biol Chem. 1998 Mar 13;273(11):6373-9
9497367
J Clin Oncol. 2004 Jun 1;22(11):2108-21
15169797
Annu Rev Biochem. 1998;67:425-79
9759494
J Am Chem Soc. 2008 Jun 25;130(25):7822-3
18512922
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Oncogene. 2004 Nov 18;23(54):8766-76
15480425
Clin Cancer Res. 2008 Aug 15;14(16):5116-23
18698029
Nature. 1999 Sep 9;401(6749):173-7
10490027
Blood. 2008 Nov 1;112(9):3835-46
18633129